Shilpa Medicare stock soars 5% after $2.5B European approval - here's why

Sometimes the pharmaceutical industry reminds us that timing really is everything. Take Shilpa Medicare, whose stock was basically doing its best impression of a deflating balloon - down 4% over the year and 3% last month - right up until the European Medicines Agency decided to throw them a lifeline worth $2.5 billion.

That lifeline came in the form of approval for their Rivaroxaban Orodispersible Films, and suddenly everyone wants a piece of Shilpa. The stock hit its 5% upper circuit limit on September 23rd, proving once again that good news travels faster than a trader's finger can hit the...